Exo trained the AI applications on more than 100,000 images from point-of-care ultrasound (POCUS) exams performed by users in real-world settings and were validated across various patient populations, health conditions and diagnostic scan types
Exo Iris now offers FDA-approved cardiac and lung AI. (Credit: Business Wire)
US-based medical imaging software provider Exo has introduced FDA-approved cardiac and lung artificial intelligence (AI) applications on its high-performance hand-held ultrasound device, Exo Iris.
Exo has received FDA 510k approvals for its AI applications in five different applications, cardiac, lung, bladder, hip, and thyroid, with plans to double the number of approvals by 2025.
The AI applications have been trained on more than 100,000 images from point-of-care ultrasound (POCUS) exams performed by users in real-world settings.
Also, they were thoroughly validated across various patient populations, health conditions and diagnostic scan types as part of the FDA approval process, said the company.
The AI identifies internal landmarks, even on less-than-perfect scans, to help caregivers get the real-time data required to make informed decisions without needing lab-quality ultrasounds.
The pocket-sized device, with affordable, AI-powered medical imaging capabilities, allows caregivers to advance diagnosis and create new care pathways for heart failure patients.
Exo co-founder and CEO Sandeep Akkaraju said: “It’s time for a reimagined approach to addressing heart failure at scale. That’s why Exo is putting AI-empowered medical imaging in the hands of every caregiver, no matter their speciality.
“Exo’s AI is simple to use, reproducible and objective, and will contribute to more accessible and reliable healthcare for all.”
Exo said that its AI-powered handheld ultrasound can reduce the threshold at the point of care and enable access to affordable medical imaging.
The company’s lung AI easily identifies the presence of B-lines with a quick scan, enabling users to quickly assess if the patient has pulmonary oedema or fluid in the lungs.
Its cardiac AI can be used by both expert and early POCUS users to quickly measure left ventricle ejection fraction (LVEF) and stroke volume in a few heartbeats.
The application measures LVEF and stroke volume in both parasternal long axis (PLAX) and apical four-chamber (A4C) views.
With the new AI capabilities, health systems and caregivers, especially those in rural and under-resourced settings, can leverage Exo Iris to obtain medical images of the heart and lungs.
In addition to cardiac and lung AI, Exo Iris now features Pulsed-Wave Doppler capabilities to support the diagnosis and deeper findings in cardiac, abdominal, and vascular applications.